arrow
Back
K

Karim Fizazi

University of Paris-Saclay

123H-index
1.5KPaper Count
8.3WCitation Count
Published Papers 474
Publication Date
Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer
err2026-08-08
err0
PREAI
errDaniel J. George; Karim Fizazi; Alicia K. Morgans; Hannah D. McManus; Yen Yen Yip; Shankar Srinivasan; Maxime Duflot; Alexander Upton; Fred Saad
errShare
errSave
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: analyses of the phase III ARASENS trial
err2026-06-12
err0
PREAI
errKarim Fizazi; Matthew R. Smith; Maha Hussain; Fred Saad; Cora N. Sternberg; E. David Crawford; Jeanny B. Aragon-Ching; Martin Schostak; Ronald Tutrone; Alicia K. Morgans; Daniel Sentana-Lledo; Heikki Joensuu; Ateesha F. Mohamed; Natasha Littleton; Shankar Srinivasan; Yvonne Buttkewitz; Rui Li; Iris Kuss; Bertrand Tombal
errShare
errSave
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
err2026-05-10
err0
PREAI
errNeal D. Shore; Karim Fizazi; Michael Thomas Schweizer; Elena Castro; Arun A. Azad; Daniel J. George; Karine Martins da Trindade; Hao Zeng; Nitin Shrivastava; Svitlana Tonkovyd; Amy Bock; Srilakshmi Nekkalapudi; Yiyun Tang; Stella Lin; Neeraj Agarwal
errShare
errSave
Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
err2026-04-05
err0
PREAI
errBertrand Tombal; Maha Hussain; Fred Saad; Karim Fizazi; Neal Shore; Evgeny Kopyltsov; Martin Bögemann; Maria J Mendez-Vidal; Natasha Littleton; Shankar Srinivasan; Frank Verholen; Matthew R. Smith
errShare
errSave
Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs
err2026-02-01
err0
errOAAI
errYu, Evan Y.; Gratzke, Christian; Burotto, Mauricio; Zhang, Alison Y.; Levesque, Eric; Ortega, Francisco; Peer, Avivit; Vile, Donald; Chen, Zheng Hong; Song, Yue; Schloss, Charles; Todoric, Jelena; Garratt, Chris; Poehlein, Christian; Antonarakis, Emmanuel S.; Fizazi, Karim
errShare
errSave
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study
err2026-01-30
err0
PREAI
errMichael Ong; Hiroyoshi Suzuki; Matthew Smith; Bertrand Tombal; Maha Hussain; Fred Saad; Karim Fizazi; Frank Verholen; Ha Pham; Shankar Srinivasan; Aly-Khan A. Lalani
errShare
errSave
Impact of androgen receptor pathway inhibitors on cognitive function in older adults treated for metastatic prostate cancer
err2025-12-23
err0
errOAAI
errAntoine Boué; Giulia Baciarello; Emmanuel Meyer; François Christy; Nedjla Allouache; Raffaele Ratta; Philippe Beuzeboc; Pierre-Emmanuel Brachet; Estelle Guerdoux; Amélie Darlix; Mathieu Boone; Sophie Gouerant; Alexandra Leconte; Justine Lequesne; Bénédicte Clarisse; Karim Fizazi; Marie Lange; Florence Joly
errShare
errSave
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer
err2025-12-22
err0
errOAAI
errLongoria, Ossian; Rekowski, Jan; Gupta, Santosh; Beije, Nick; Pantel, Klaus; Efstathiou, Eleni; Sternberg, Cora; Castellano, Daniel; Fizazi, Karim; Tombal, Bertrand; Sharp, Adam; Sartor, Oliver; Mace, Sandrine; Geffriaud-Ricouard, Christine; Wenstrup, Richard; De Wit, Ronald; De Bono, Johann
errShare
errSave
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
err2025-12-17
err0
errOAAI
errSoumyajit Roy; Yilun Sun; Maha Hussain; Kim N. Chi; Karim Fizazi; Ian D. Davis; Susan Halabi; Neeraj Agarwal; Simon Chowdhury; Bertrand Tombal; Scott C. Morgan; Shawn Malone; Pedro C. Barata; Michael Ong; Christopher J. D. Wallis; Alejandro Berlin; Umang Swami; Amar U. Kishan; Angela Y. Jia; Nicholas G. Zaorsky; Jorge A. Garcia; Prateek Mendiratta; Jason R. Brown; Vinod V. Subhash; Martin R. Stockler; Hayley Thomas; Rana R. McKay; Eric J. Small; Neal D. Shore; Fred Saad; Christopher J. Sweeney; Daniel E. Spratt
errShare
errSave
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024
err2025-11-21
err0
PREAI
errUrsula M. Vogl; Sara Merler; Antonio Angrisani; Fabio Turco; Ian D. Davis; Jason A. Efstathiou; Karim Fizazi; Nicholas D. James; Neal Shore; Eric J. Small; Matthew R. Smith; Christopher J. Sweeney; Bertrand Tombal; Thomas Zilli; Ken Herrmann; Aurelius Omlin; Silke Gillessen
errShare
errSave
Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]
err2025-11-13
err0
PREAI
errArun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal
errShare
errSave
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis
err2025-11-04
err0
PREAI
errIrbaz Bin Riaz; Syed Arsalan Ahmed Naqvi; Kunwer Sufyan Faisal; Huan He; Kaneez Zahra Rubab Khakwani; Daniel S. Childs; Jacob J. Orme; Praful Ravi; Parminder Singh; Syed A. Hussain; Kim Chi; Neeraj Agarwal; Axel S. Merseburger; Ian D. Davis; Andrew Armstrong; Maha H. Hussain; Matthew Smith; Gerhardt Attard; Bertrand Tombal; Karim Fizazi; Nick James; Aurelius Omlin; Silke Gillessen; Mohammad Hassan Murad; Eliezer M. Van Allen; Christopher J. Sweeney; Alan Haruo Bryce
errShare
errSave
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial
err2025-11-04
err0
errOAAI
errJoan Carles; Bertrand Tombal; Maha Hussain; Fred Saad; Karim Fizazi; Álvaro Montesa Pino; Maria José Méndez-Vidal; Alejo Rodriguez-Vida; Daniel Castellano; Pablo Borrega; Patrick Adorjan; Cristina Moretones; Manjari Dissanayake; Matthew R. Smith
errShare
errSave
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)
err2025-11-01
err0
PREAI
errMorgans, Alicia K.; Chehrazi-Raffle, Alex; Niazi, Tamim; Shore, Neal D.; Ross, Ashley E.; Roder, Andreas; Gomes, Andrea Juliana; Supiot, Stephane; Barthelemy, Philippe; Hatano, Koji; Ruiz, Carmen Belen Congregado; Yoshida, Soichiro; Herrera-Imbroda, Bernardo; Gratton, Matthieu; Gschwend, Jurgen E.; Hope, Thomas A.; Joensuu, Heikki; Kuss, Iris; Le Berre, Marie-Aude; Dimova-Dobreva, Miryana; Fizazi, Karim
errShare
errSave
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations—Genomic Features Associated with Response to Therapy
err2025-10-30
err0
PREAI
errKarim Fizazi; Johann S. de Bono; A. Douglas Laird; Philippe Barthélémy; Rémy Delva; Tanya Dorff; Marco Maruzzo; Adam Stirling; Jean-Pascal Machiels; Herlinde Dumez; Vincent Renard; Julia F. Hopkins; Lee A. Albacker; Hsiang-Chun Chen; Cynthia G. Healy; Liza DeAnnuntis; Jijumon Chelliserry; Inge M. van Oort; Giorgio V. Scagliotti; Niven Mehra
errShare
errSave
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study
err2025-10-19
err0
errOAAI
errKarim Fizazi; Noel W. Clarke; Maria De Santis; Hirotsugu Uemura; Andre P. Fay; Nuri Karadurmus; Mariusz Kwiatkowski; Carlos Alvarez-Fernandez; Shusuan Jiang; Miguel Sotelo; Dominique Parslow; Niara Oliveira; Tae Gyun Kwon; Dingwei Ye; Steve Boudewijns; Pongwut Danchaivijitr; Claire Rooney; Christopher Gresty; Marc Yeste-Velasco; Jill Logan; Daniel J. George
errShare
errSave
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond
err2025-09-29
err0
errOAAI
errAlice Bernard-Tessier; Natacha Naoun; Solenn Barraud; Ronan Flippot; Cedric Pobel; Macarena Rey; Capucine Baldini; Christophe Massard; Anna Patrikidou; Alina Fuerea; Mario Di Palma; Laurence Albigès; Yohann Loriot; Karim Fizazi
errShare
errSave
Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis
err2025-09-29
err0
errOAAI
errS.C. Yazgan; E. Yekedüz; E. Akkuş; M. Sun; S. Gillessen; K. Fizazi; R.R. McKay; C. Ay; E. Castro; N. Agarwal; T.K. Choueiri; Y. Ürün
errShare
errSave
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial
err2025-09-27
err0
PREAI
errAdrien Rousseau; Maryam Karimi; Stefan Michiels; Guilhem Roubaud; Xavier Maldonado; Stephane Supiot; Ray McDermott; Aude Flechon; Bertrand Tombal; Philippe Ronchin; Dominik Berthold; Jean-François Berdah; Gabriel Kacso; Gwenaelle Gravis; Fabio Calabro; Sophie Tartas; Xavier Muracciole; Helene Ribault; Karim Fizazi; Stéphanie Foulon
errShare
errSave
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
err2025-09-13
err0
PREAI
errKen Herrmann; Jochen Walz; Steven MacLennan; Alberto Briganti; Philip Cornford; Johannes Czernin; Matthias Eiber; Stefano Fanti; Wolfgang P. Fendler; Karim Fizazi; Andrei Gafita; Silke Gillessen; Karolien Goffin; Boris Hadaschik; Michael S. Hofman; Thomas A. Hope; Tobias Maurer; Alicia K. Morgans; Michael J. Morris; Declan G. Murphy; Daniela E. Oprea-Lager; Piet Ost; Joe M. ÓSullivan; Olivier Rouvière; Shahneen Sandhu; Oliver Sartor; Mike Machaba Sathekge; Clare Tempany; Wim Witjes; Louise Emmett; Anders S. Bjartell
errShare
errSave